TAS-120 (futibatinib)
oral irreversible FGFR1-4 inhibitor in Ph. I-III trials for FGFR+ advanced tumors from structure-based design Cancer Res., Sep. 24, 2020 Taiho Pharmaceutical, Tokyo, JP
Molecules of the Month - September 2020
Molecules of the Month
- FGF401 (roblitinib)
- TNO155
- BMS-986143
- AZD9833
- AL-611
- PF-06882961
- PF-05221304
- PF-06835919
- "compound 9"
- GLPG1205
- OP-5244
- SCO-267
- "compound 23"
- TAS-120 (futibatinib)